Scholar Rock Holding Corporation
SRRK
株式のランク
#3308
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
株価
$43.16
最終同期: 2026-10-21
時価総額
$5.26B
変化（1日）
4.35%
変化（1年）
51.33%
国
US
取引 Scholar Rock Holding Corporation (SRRK)
カテゴリー
Healthcare
Scholar Rock Holding Corporation（SRRK）の株価履歴
終値の最高値: $42.18 （2026-10-01）
終値の最安値: $16.12 （2018-05-01）
終値の最安値: $16.12 （2018-05-01）
Scholar Rock Holding Corporation の株価履歴（2018 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 3.69% |
| 2025 | 4.21% |
| 2024 | 139.27% |
| 2023 | 123.69% |
| 2022 | -68.52% |
| 2021 | -46.82% |
| 2020 | 347.42% |
| 2019 | -54.48% |
| 2018 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
